Background-Among patients undergoing transcatheter pulmonary valve (TPV) replacement with the Melody valve, risk factors for Melody stent fracture (MSF) and right ventricular outflow tract (RVOT) reintervention have not been well defined. , 150 patients (median age, 19 years) underwent TPV implantation in the Melody valve Investigational Device Exemption trial. Existing conduit stents from a prior catheterization were present in 37 patients (25%, fractured in 12); 1 or more new prestents were placed at the TPV implant catheterization in 51 patients. During follow-up (median, 30 months), MSF was diagnosed in 39 patients. Freedom from a diagnosis of MSF was 77Ϯ4% at 14 months (after the 1-year evaluation window) and 60Ϯ9% at 39 months (3-year window). On multivariable analysis, implant within an existing stent, new prestent, or bioprosthetic valve (combined variable) was associated with longer freedom from MSF (PϽ0.001), whereas TPV compression (Pϭ0.01) and apposition to the anterior chest wall (Pϭ0.02) were associated with shorter freedom from MSF. Freedom from RVOT reintervention was 86Ϯ4% at 27 months. Among patients with a MSF, freedom from RVOT reintervention after MSF diagnosis was 49Ϯ10% at 2 years. Factors associated with reintervention were similar to those for MSF. Conclusions-MSF was common after TPV implant in this multicenter experience and was more likely in patients with severely obstructed RVOT conduits and when the TPV was directly behind the anterior chest wall and/or clearly compressed. A TPV implant site protected by a prestent or bioprosthetic valve was associated with lower risk of MSF and reintervention. Clinical Trial Registration-URL: http://www.clinicaltrials.gov. Unique identifier: NCT00740870. (Circ Cardiovasc Interv. 2011;4:602-614.)
T ranscatheter pulmonary valve (TPV) placement was first reported in 2000. 1 Beginning in January 2007, the Melody TPV (Medtronic Inc, Minneapolis, MN) was implanted in 150 patients at 5 US centers under an Investigational Device Exemption (IDE, No. G050186) protocol for treatment of right ventricular outflow tract (RVOT) dysfunction. In January 2010, enrollment in the IDE trial was completed, and the Melody valve was approved for placement in dysfunctional RVOT conduits as a palliative measure aimed at delaying surgical intervention.
One of the clinical and regulatory concerns with the Melody valve has been fracture of the balloon-expandable stent in which the bovine jugular venous valve is housed. In early reports from Europe, survival free from Melody valve stent fracture (MSF) was 85% at 1 year and 75% at 2 years after implant. 2 A similar trend was observed in preliminary analyses of the US IDE cohort. 3, 4 An important incidence of fracture has also been reported in bare metal stents (BMS) placed for RVOT conduit obstruction or central branch pulmonary arterial stenosis. [5] [6] [7] Risk factors for stent fracture
WHAT IS KNOWN
• Transcatheter pulmonary valve placement with the Melody valve is effective in the short term for relief of right ventricular outflow tract obstruction and pulmonary regurgitation in patients with surgically implanted right ventricle-to-pulmonary artery conduits. • Stent fracture with associated right ventricular outflow tract obstruction is the most common indication for reintervention after Melody valve placement, but risk factors for stent fracture and reintervention have not been determined.
WHAT THE STUDY ADDS
• In this series of 150 patients who underwent Melody valve implant as part of the US Investigational Device Exemption trial, we analyzed implant conditions, conduit preparation techniques, and valverelated outcomes and documented an ongoing risk of stent fractures, many of which were not associated with hemodynamic valve dysfunction. • We found that stent fractures were more likely in patients with severely obstructed right ventricular outflow tract conduits and when the Melody was directly behind the anterior chest wall and/or clearly compressed, whereas a valve implant site protected by a prestent or bioprosthetic valve was associated with lower risk of fracture and reintervention.
in those series included implantation directly behind the sternum or in direct apposition to the thoracic aorta, and stent compression or recoil after deployment, findings that imply that there are mechanical environments within the mediastinum that may predispose to more extreme loading and consequent fracture of balloon-expandable stents. 2, 6, 7 Computational modeling suggests that multiple concentric stents should have superior radial strength to a single stent. 8 However, analytic simulations of stent strength are typically based on idealized conditions. 9,10 Using patient-specific modeling, Schievano et al demonstrated that the geometry of the deployed Melody valve in the RVOT may not be ideal; thus, the assumptions used during standard radial strength testing may substantially underestimate in vivo stent loading conditions. 9 -11 In accordance with the theoretical benefit of implanting multiple stents to increase radial strength, "prestenting" the conduit with BMS or covered stents before TPV placement has become routine at many centers. [12] [13] [14] Recent data suggest that prestenting may be associated with better gradient relief and protection against MSF, 12 but otherwise, little is known about the relationship between prestenting, other patient-related and technical factors, and outcomes after Melody valve implant.
Recurrent RVOT obstruction associated with MSF is the most common indication for reintervention after Melody valve placement. 4, 15 To deploy TPV technology with optimal clinical benefit and cost-effectiveness, it is critical to understand risk factors for and means to prevent MSF and related TPV dysfunction. In the present study, we assess risk factors for MSF, valve dysfunction, and reintervention after TPV placement in the complete IDE cohort after all patients had reached the 1-year follow-up interval.
Methods

Patients and Study Protocol
The Melody valve IDE trial was a prospective, nonrandomized, multicenter study of TPV placement in dysfunctional RVOT conduits. The original and expanded versions of the protocol and earlier trial outcomes were reported previously. 3, 4 Patients were categorized according to primary implant indication, based on the hemodynamic inclusion criteria met at the time of enrollment. 3, 4 If the patient met only the pulmonary regurgitation (PR) or RVOT obstruction criteria, the primary indication was "regurgitation" or "stenosis," respectively; if the patient met both criteria, the primary indication was "mixed." For the purposes of analysis, patients meeting the stenosis criterion (stenosis or mixed indication) were considered as a combined group.
Follow-up evaluations were conducted at prespecified intervals (3, 6, and 12 months, then annually) at the implanting center. For the current study, the database was closed for analysis on April 20, 2011, after the full study cohort of 150 implanted patients had completed the 1-year follow-up evaluation or withdrawn from the study for death, valve explant, or loss to follow-up. Patients who were enrolled in the trial and underwent catheterization with intention to treat but did not have a TPV implanted were excluded from this study.
All versions of the protocol were approved by the US Food and Drug Administration, Center for Devices and Radiological Health, as well as the institutional review board at each institution. The trial is registered in ClinicalTrials.gov (Identifier: NCT00740870).
Catheterization and Valve Implantation
In the original catheterization protocol (Figure 1 ), additional procedures, including prestenting of the conduit, were not permitted. The intent of this policy was to minimize confounding in the assessment of the safety of TPV implantation, particularly given that stents commonly used for prestenting were not approved for implantation in RVOT conduits. However, after the first 35 implants, the protocol was modified to allow prestenting or other concomitant interventions, although no clinical criteria or technical parameters were specified for such procedures. Because patients may have had existing intact or fractured stents in the conduit from a prior catheterization (existing prestent) and/or undergone prestenting with varying types and numbers of stents at the TPV implant catheterization (new prestent), prestenting data were reported and analyzed using multiple different designations. For some of these classifications, intact (ie, unfractured) prestents from a prior catheterization were grouped with new prestents ("any intact prestent"). Also, because bioprosthetic valves (BPV) are mounted in a rigid frame, which presumably protects the TPV in a similar manner to a conduit stent, prestented conduits were also grouped with BPV for the purposes of analysis. After the first 70 implants, the protocol was modified explicitly to permit TPV implant in BPV that were not housed within a circumferential conduit.
Fluoroscopic/Angiographic Assessments
Images from the implant catheterization and follow-up radiographic studies were reviewed for predetermined conduit-and stent-related variables. By protocol, MSF was ascertained with chest radiograms at the 3-month, 1-year, and annual follow-up visits and multiplane fluoroscopy at the 6-month visit. MSF were graded by the implanting physician according to the classification proposed by Nordmeyer et al: type I, fracture of Ն1 strut without loss of stent integrity; type II, fracture with loss of stent integrity; and type III, fracture associated with separation of fragments or embolization. 2 MSF diagnoses and grades were not confirmed by a core laboratory. There was no systemic assessment or recording of fractures that occurred in conduit prestents independent from MSF. The narrowest preinter-vention conduit diameter was measured and reported by the implanting physician. Other radiographic analyses were performed by a single investigator who was blinded to outcome. The location of the implanted Melody valve relative to the sternum or anterior chest wall was characterized as remote, partially apposed (Ͻ50% of length of stent), or substantially apposed (Ͼ50% of length of stent). TPV compression at the completion of the implant procedure was defined as an eccentricity index (ratio of the narrowest valve dimension in the 2 fluoroscopic projections, with the smaller dimension in the denominator) Ͼ1.1. Further details and definitions are presented in the online-only Data Supplement Materials.
Statistical Analysis
Data are presented as meanϮSD, median (range), or frequency (percent of cohort). Time-related outcomes including freedom from a diagnosis of any MSF, freedom from a diagnosis of type II MSF, freedom from RVOT reintervention related to TPV dysfunction (ie, excluding conduit explant due to acute procedural complications), and freedom from a diagnosis of TPV dysfunction (moderate or greater PR or mean Doppler RVOT gradient Ն35 mm Hg, or reintervention) were analyzed. Patients who underwent conduit explant due to acute procedural complications or who died before the first protocol follow-up window (3 months) were censored event-free at the time of explant or death. For analysis of freedom from reintervention, patients who underwent conduit explant due to acute procedural complications were not included, and patients who did not meet event criteria were censored at the last date they were known to be alive and in follow-up (includes patients later lost to follow-up). For analyses of freedom from a diagnosis of MSF or TPV dysfunction, patients without events were censored at the most recent follow-up evaluation for which radiographic or echocardiographic data were available, respectively. Freedom-from-event analyses were performed using Kaplan-Meier and Cox regression analysis. Multivariable Cox regression models were constructed using selected combinations of variables significant to PϽ0.01 on univariable analysis, entered in a forward stepwise manner. Variables were prioritized for inclusion in the multivariable model, based on the strength of the univariate hazard ratio, tightness of the confidence ranges, and face validity, avoiding collinear or similar variables in any given model. Based on the number of events for the outcome in question, models were built with 6 or fewer variables available for selection, and no more than 2 or 3 in the final model. The results of the final models are presented in the text. The variables listed in Tables 1 and 2 were analyzed as predictor variables in univariable freedom-from-event analyses. Hazard ratios (HR) are presented with 95% confidence intervals (CI). Between-group differences in categorical predictor variables were assessed using 2 analysis and reported with odds ratios (OR) and 95% CI. Differences in continuous variables were assessed with independent-samples t test or Wilcoxon rank sum test.
Results
Patients
From January 2007 through January 2010, 150 patients (87 male, 64%) were enrolled and underwent Melody valve implantation at a median age of 19 years (7-53 years). Demographic, historic, and diagnostic data are summarized in Table 1 . Patients with a primary implant indication of stenosis or mixed disease were younger than those with a primary indication of PR (19.7Ϯ8.9 versus 23.3Ϯ9.8 years, Pϭ0.02). Other differences relating to the primary implant indication are detailed in the online-only Data Supplement Materials.
Procedural and Acute Outcomes
Procedural and fluoroscopic data are summarized in Table 2 . One or more existing conduit stents from a prior catheteriza- After the first 35 implants, this protocol was modified to allow concomitant procedures during the same catheterization, including prestenting of the conduit, which could be performed after predilation and before balloon sizing. The following conditional parameters were specified. The minimum predilation balloon pressure was not specified, but it was intended that inflation pressures Ͼ8 atm would be used as necessary to eliminate any stenotic waist. The high-pressure balloon diameter should be at least 2 mm larger than narrowest diameter of the conduit, less than 110% of nominal conduit diameter, and less than 20 mm. Balloon sizing should be done using a balloon with a diameter at least 4 mm larger than the narrowest angiographic diameter (after predilation), and inflated to a pressure no higher than 8 atm. RVOT indicates right ventricular outflow tract; TPV, transcatheter pulmonary valve. tion were present in 37 patients (25%); these were noted to be fractured at the beginning of the implant catheterization in 12 patients and fractured during predilation in 2 others. One or more new prestents were placed at the TPV implant procedure in 51 patients (34% overall, 44% of patients in whom prestenting was allowed by the protocol). Among 84 new prestents implanted, stent types included 49 Palmaz XL (Palmaz Scientific, Dallas, TX), 27 IntraStent Max LD (eV3 Inc., Plymouth, MN), 4 Palmaz Genesis XD (Cordis Corporation, Miami, FL), and 4 Covered CP Stent (NuMed, Inc, Hopkinton, NY). As depicted in online-only Data Supplement Figure I, there was considerable variation among centers in conduit preparation procedures.
Acute hemodynamic outcomes are summarized in Table 2 and depicted in online-only Data Supplement Figure II . There were no differences in the postimplant peak RVOT gradient obtained in the catheterization laboratory or the discharge mean Doppler RVOT gradient according to conduit preparation techniques (eg, predilation balloon size or pressure, prestenting, postdilation). However, patients with a primary implant indication of stenosis or mixed disease had a modestly higher postimplant peak RVOT gradient (14.2Ϯ5.7 versus 12.2Ϯ7.0 mm Hg, Pϭ0.05) and discharge mean Doppler RVOT gradient (23.2Ϯ9.2 versus 17.5Ϯ7.0 mm Hg, Pϭ0.001) than patients with PR as the primary indication. Compression of the implanted TPV was more common in patients with an implant indication of stenosis/mixed disease (OR, 3.3 [1.01-9.1], Pϭ0.04), a peak gradient before intervention Ն40 mm Hg (OR, 3.6 [1.2-10.7], Pϭ0.02), a smaller ratio of angiographic conduit diameter to original diameter (0.50Ϯ0.12 versus 0.62Ϯ0.17, Pϭ0.005), or substantial ap- As described in our previous report, there was 1 conduit rupture during the implant procedure that was treated with conduit replacement, and 1 patient died within 30 days of TPV implant. 4 There were no other procedural complications treated with surgery or leading to death or TPV explant.
Follow-Up
Patients
Among the 148 patients included in the follow-up evaluation, the median duration from implant to database closure or removal from the protocol was 30 months (5-51 months). One patient died of unknown causes 2 years after implant, with no evidence of valve dysfunction or MSF at the most recent evaluation 2 months earlier; no autopsy was performed. Two patients underwent Melody valve explant 5 and 21 months after implant (see below) and thereafter were no longer followed according to the protocol. Three patients were considered lost to follow-up after missing a scheduled follow-visit (1 each after the discharge, 3-month, and 1-year evaluations). Among the remaining 142 patients who were alive and in current follow-up, the most recent follow-up evaluation completed was at 1 year in 47, 2 years in 63, 3 years in 27, and 4 years in 5.
Stent Fracture
MSF was diagnosed in 39 patients, 11 initially at the 3-month evaluation, 15 at 6 months, 6 at 1 year, 6 at 2 years, and 1 at 3 years. In all but 6 of these patients, the MSF was initially classified as type I (online-only Data Supplement Figure III) . A total of 17 patients were diagnosed with a type II MSF, either at the time of initial identification (nϭ6) or after prior diagnosis of a type I MSF (ie, progression from type I to type II; nϭ11) ( Figure 2) . One patient had a type II MSF with embolization to the RV of a single strut segment (type III). Other structural changes associated with type II MSF are depicted in the online-only Data Supplement videos.
As shown in Figure 3 , freedom from a diagnosis of MSF was 77Ϯ4% at 14 months (after the 1-year evaluation window), 68Ϯ5% at 27 months (after the 2-year window), and 60Ϯ9% at 39 months (after the 3-year window). Freedom from a diagnosis of type II MSF was 85Ϯ4% at 27 months and 74Ϯ11% at 39 months.
Variables associated with freedom from MSF to PϽ0.10 on univariable analysis are summarized in Table 3 . On multivariable analysis, the combined variable "implant within any intact prestent or BPV" was associated with longer freedom from a diagnosis of MSF and both TPV compression and substantial apposition to the anterior chest wall were associated with shorter freedom from MSF (Table 4 and Figure 4 ). On multivariable analysis of factors associated with freedom from diagnosis of a type II MSF, the same factors were significant (Table 4 ). Exploratory analyses did not disclose any marked interactions between factors included in multivariable analysis, indicating that the factors were relatively independent of each other. When the combined variable "implant within any intact prestent or BPV" was replaced with "implant within any intact present," it remained significant in the model for any MSF, but not for type II MSF. Freedom from a diagnosis of MSF did not differ between patients with a single prestent and those with multiple prestents (online-only Data Supplement Figure IV) .
Among 39 patients diagnosed with a MSF, the TPV was implanted within a BPV in 1, a new prestent in 3 (1 with multiple, nonoverlapping new prestents; 2 with a prior fractured prestent), a prior intact prestent without a new prestent in 6, and a prior fractured prestent without a new prestent in 3. Among the 17 patients with a type II MSF, the TPV was implanted within a new prestent (single) in 1, a prior fractured prestent without a new prestent in 2, but none with an intact prior prestent or a BPV. Only 1 patient with a BPV had MSF, which occurred in a portion of the stent that was proximal to the BPV ring and directly retrosternal (online-only Data Supplement Figure III) .
Among the 33 patients initially diagnosed with a type I MSF, freedom from diagnosis of a type II MSF was 71Ϯ9% at 1 year and 56Ϯ12% at 2 years after the initial MSF diagnosis. TPV compression was associated with shorter freedom from progression to a type II MSF (HR, 4.0 [1.1-14.0], Pϭ0.03).
Melody Valve Dysfunction
Melody valve dysfunction was documented in 24 patients, all of whom had a mean Doppler RVOT gradient Ն35 mm Hg or underwent reintervention; there were no cases of moderate or severe PR. Four of these patients had hemodynamic dysfunction but did not undergo reintervention. Two other patients reached the echocardiographic threshold for dysfunction (mean RVOT gradient Ն35 mm Hg) at 1 follow-up time point but had a lower gradient at subsequent evaluation; these patients were near the dysfunction threshold on the most recent echocardiogram (mean RVOT gradient 33 and 34 mm Hg, respectively) but were not coded as having dysfunction. As shown in online-only Data Supplement Figure III , patients with a diagnosis of type II MSF had higher RVOT gradients during follow-up than those with no MSF or a type I MSF.
Freedom from Melody valve dysfunction was 88Ϯ3% at 14 months, 87Ϯ3% at 27 months, and 73Ϯ7% at 39 months.
Variables associated with freedom from valve dysfunction are summarized in Table 3 . In general, these were similar to factors associated with MSF, but the post-TPV RVOT gradient was more important. On multivariable analysis, a higher mean Doppler RVOT gradient early after implant and TPV compression were associated with shorter freedom from TPV dysfunction, and implant within any intact prestent or BPV was associated with longer freedom from dysfunction (Table  4 ). When "implant within any intact prestent or BPV" was replaced in the model by "implant within any intact present," it remained significant.
Melody Valve Reintervention
Twenty patients underwent RVOT reintervention during the follow-up period, initially consisting of Melody valve redilation in 5 patients, implantation of a second TPV within the first 16 in 14, and surgical RVOT conduit replacement in 1 (Figures 2 and 5 ). Two of the 5 patients who underwent TPV redilation subsequently had another catheterization, at which a second TPV was implanted. One of the 16 patients in whom a second TPV was implanted subsequently underwent conduit replacement. All of the patients who underwent a second TPV implant or surgical RVOT reintervention had a MSF, and all but 2 had a type II MSF. None of the patients who underwent Melody valve redilation alone had a documented MSF. Only 1 patient with a BPV underwent reintervention, which consisted of redilation without implant of a second TPV.
Freedom from RVOT reintervention was 92Ϯ2% at 14 months and 86Ϯ4% at 27 months (Figure 3 ). Variables associated with freedom from reintervention are summarized in Table 3 (also see Figure 6 ). On multivariable analysis, a higher mean Doppler RVOT gradient post-TPV and TPV compression were associated with shorter freedom from reintervention, and implant within any intact prestent or BPV was associated with longer freedom from reintervention (Table 4 ). When "implant within any intact prestent or BPV" was replaced by "implant within any intact present," it remained significant. Among patients in whom the Melody valve was substantially apposed to the anterior chest wall, freedom from RVOT reintervention was significantly longer in those who had the TPV implanted within an intact prestent or BPV than those who did not (90Ϯ10% versus 54Ϯ13% at 27 months, Pϭ0.02).
Among the 39 patients with a documented MSF, freedom from RVOT reintervention after diagnosis of the MSF was 68Ϯ8% at 1 year and 49Ϯ10% at 2 years. On multivariable analysis, TPV compression (OR, 3.3 [1.2-9.3], Pϭ0.02) and a higher post-TPV mean RVOT gradient (HR, 1.06 per mm Hg [1.01-1.12], Pϭ0.02) were associated with shorter freedom from reintervention after the diagnosis of a MSF.
Discussion
Stent Fracture
In the US IDE trial, fracture of the platinum-iridium stent frame of the Melody TPV was common after implantation in dysfunctional RVOT conduits, with 68Ϯ5% freedom from any MSF at 2 years. Fewer than half of the documented MSF were associated with loss of stent integrity. These outcomes were similar to the initial experience of Bonhoeffer's group. 2 Given that MSF is a function of fatigue stress, we suspect that there will be an ongoing hazard for new MSF and for progression of minor MSF to more substantial MSF, which is supported by the fact that we detected new MSF as late as 3 years after implant and that there was continued progression from type I to type II MSF 2 years after the initial diagnosis of MSF.
A number of factors were associated with MSF on univariable analysis, many of which were interrelated. Variables reflecting more severe conduit obstruction were associated with shorter freedom from a diagnosis of MSF, including a primary implant indication of stenosis or mixed disease, younger age (associated with a primary implant indication of stenosis or mixed disease), a higher RVOT gradient before and after intervention, smaller angiographic diameter of the conduit, and a smaller ratio of the angiographic diameter to the original diameter. Other factors associated with shorter freedom from MSF were related to the environment in which the TPV was implanted, such as substantial apposition to the anterior chest wall, TPV compression, and dynamic compressive deformation of the implanted TPV. In contrast, patientrelated or procedural variables reflecting a mechanically protected TPV were associated with longer freedom from MSF, including implant within a BPV rather than a homograft or other conduit, and prestenting of the conduit with 1 or more BMS.
Melody Valve Dysfunction and RVOT Reintervention
Although much attention has been drawn to the issue of MSF in assessment of the safety and efficacy of the Melody valve, it is not MSF per se that is important, but rather the consequences of MSF. The most obvious and common adverse outcomes associated with MSF are TPV dysfunction and consequent RVOT reintervention. Although TPV dysfunction and reintervention in this series were almost always associated with MSF, freedom from diagnosis of a type II MSF after the initial MSF diagnosis was only 56Ϯ12% and freedom from reintervention was 49Ϯ10%, suggesting that progression of a type I MSF to a hemodynamically important MSF is not universal. Thus, whereas MSF are frequently of obvious and progressive clinical importance, they are not always, and, as such, the dialogue should be refocused from "stent fracture" to "clinically important stent fracture."
Most of the factors associated with TPV dysfunction and RVOT reintervention were the same as those associated with MSF. Once a MSF was diagnosed, the only factor associated with shorter freedom from reintervention was compression of the TPV at the completion of the implant procedure, which is consistent with the conclusion that a MSF in a setting of obvious mechanical stress on the conduit is more likely to be hemodynamically important.
Predilation, Prestenting, and Postdilation
Preparation of the Melody valve implant site is an important consideration for optimizing the hemodynamic outcome of Melody valve implantation, particularly relief of RVOT obstruction. 
Prestenting
In this series, prestenting was clearly associated with a longer freedom from diagnosis of MSF, TPV dysfunction, and RVOT reintervention, but no difference in acute postimplant RVOT gradient. In the only prior study to evaluate the effect of prestenting before TPV implant, patients who underwent prestenting had lower acute postimplant RVOT gradients and a lower hazard for MSF, but there was no difference in reintervention. 12 Assessing the impact of prestenting on MSF in our cohort is confounded by the fact that prestenting was prohibited during the initial 35 implants, after which it was permitted and performed in 43% of patients. However, there was no defined protocol and prestenting practices varied among investigators. Also, a subset of patients had varying numbers and types of existing RVOT stents from prior catheterizations. Some of these stents were documented to be fractured at the time of TPV implantation, and others had been in place for many years and were likely affected by fatigue-related changes. Thus, simple categorization of prestenting could not account for complexity within this factor. This series was not powered to analyze whether different types of prestents conferred more durable protection against MSF.
Almost half of the patients who underwent prestenting received multiple stents. Although freedom from MSF was not statistically related to the number of prestents, the study was not powered to answer this question, and the Kaplan-Meier curves did begin to diverge when both new and existing prestents were considered. This analysis also may have been confounded by treatment bias, with investigators inclined to implant multiple prestents in patients they assessed to be at higher risk for MSF. Whether there are patients in whom multiple prestents provide important additive protection against MSF deserves further study.
Identification of patients who are more and less likely to benefit from prestenting is important. Although it may be simpler to perform prestenting routinely, there are likely risks to prestenting above and beyond those incurred with TPV implantation alone, and it may be prudent to avoid such risks if there is no incremental benefit of prestenting in a given patient. This study provides only limited insight in this regard, due to limited power and heterogeneity in prestenting practices. Given that patients with a BPV rarely underwent prestenting and did not develop type II MSF or undergo RVOT reintervention associated with MSF, it seems that important MSF is uncommon when a Melody valve is implanted in a BPV even without prestenting. Although this study did not allow discrimination of other groups of patients in whom prestenting offers minimal or no benefit, we identified important risk factors that can be ascertained before TPV implant, including apposition of the likely TPV implant site to the chest wall, higher conduit gradient, and more severe conduit narrowing. Among patients with apposition of the implanted Melody valve to the chest wall, those with an intact prestent or BPV had significantly longer freedom from RVOT reintervention than those that did not, although the number of patients was small. Taken together, these findings suggest that prestenting is likely to be beneficial and may be indicated when substantial chest wall apposition or conduit obstruction are present.
Predilation and Postdilation
Predilation of the conduit and postdilation of the implanted TPV are other potentially important methods of optimizing the outcome of TPV placement. In the US IDE protocol, predilation of the conduit was required. When performed appropriately, predilation, often using high-pressure balloons, should tear or break the substrate of obstruction. Once this is accomplished, we speculate that residual strain in the conduit wall is reduced relative to its prior state, allowing plastic deformation of the prestent and/or TPV to a larger diameter with less recoil from elastic deformation of the conduit. Thorough predilation should not be seen simply as an alternative to prestenting, although it may be in some cases, but rather as a complement to it. Balloon waists that form during predilation allow identification of the focal point of the lesion and/or the presence of multiple lesions, which should facilitate proper balloon selection, Figure 5. A and B , Anteroposterior and lateral fluoroscopic images demonstrating compression of the implanted Melody valve stent in a patient with a heavily calcified right ventricular outflow tract homograft conduit that is directly apposed to the anterior chest wall. C, Aortic root angiogram in a caudal left anterior oblique projection demonstrates distortion and compression of the Melody valve from the rightward posterior aspect by a dilated neoaortic root in a patient with conduit obstruction after a Ross procedure. D, After placement of 2 bare metal stents and a second transcatheter pulmonary valve within the fractured Melody valve, the cylindrical valve can be seen to indent the dilated neoaortic root. understanding of conduit compliance, and adequate treatment of unanticipated lesions.
Postdilation after TPV implant was performed in 47% of patients. Although postdilation is not "preparation" for Melody valve implant per se, some of the theoretical benefits of predilation also pertain to postdilation, namely, tearing/cracking the conduit and increasing the final caliber of the implanted TPV. However, postdilation is performed after the TPV is implanted and thus allows less flexibility than predilation: if it results in injury to the conduit wall or is ineffective, it may not be possible to relieve the obstruction or treat the tear without compromising TPV function. In theory, there are other potential drawbacks to postdilation. The absence of significant PR in this series suggests that postdilation does not pose an acute risk to the leaflets, but any impact on long-term valve function remains to be determined. Also, postdilation may impose high focal stress on TPV stent struts. Our data provide no insight into these theoretical considerations, but they may be important.
Because the various conduit preparation techniques were used without strict prescription, and the same heterogeneity that was seen in prestenting also applied to predilation and postdilation practices, we cannot draw conclusions about the independent impact of predilation and/or postdilation from this study.
Limitations
Assessment of MSF in this study was of limited sensitivity and resolution for a combination of reasons. Radiography was performed at predetermined intervals, so the precise timing of MSF could not be defined. Biplane chest radiography, used for evaluation of MSF at all but the 6-month evaluation, may not profile the stent clearly in both views. Multiplane fluoroscopy, which we assumed would be more sensitive for detection of MSF, was only performed routinely at the 6-month evaluation. Additional stents in the RVOT conduit may confound the visualization of fractured TPV stent struts because of radiographic interference and reduction of displacement at fracture points. For all of these reasons, it is possible that subtle MSF may have been missed or ascertainment delayed, although the clinical importance of such MSF is likely to be minimal. The grading scale we used for MSF is imprecise, with the distinction between types I and II hinging on "stent integrity," which is not defined and may be variably interpreted, and there was no core laboratory assessment to ensure consistency. It is likely that many patients with existing prestents had an underlying obstructive substrate of conduit dysfunction that was not reflected in baseline data due to the prior stent, which may have confounded assessment of risk factors for MSF. Also, there may have been important factors not assessed or included in our analyses, such as TPV "recoil." Similarly, due to difficulty distinguishing solid body motion from more complex stent motion, our assessment of the dynamic mechanical environment of the implanted TPV was qualitative and simplistic. Two midstudy protocol modifications allowing implantation within a BPV and prestenting after the first 70 and 35 patients, respectively, may have confounded our outcome evaluations. Similarly, institutional practice variation regarding predilation, prestenting, and postdilation confounded assessment of the independent importance of these technical factors.
Conclusions
MSF was common after Melody valve implant in this multicenter experience and was more likely in patients with smaller and more obstructed RVOT conduits, those with homografts rather than BPV, and when the implanted TPV was directly behind the anterior chest wall and/or compressed. Melody valve implant within a protected RVOT, either a BPV with a rigid frame or a prestented conduit, was associated with lower risks of MSF, TPV dysfunction, and reintervention. However, the small number of clinically important outcomes precluded robust multivariable or subgroup analysis. Aside from those with a BPV, it is not yet possible to define patients who will or will not benefit from prestenting, although direct apposition of the conduit to the anterior chest wall and severe conduit obstruction are factors associated with MSF that can be identified a priori and may be reasonable indications for prestenting. These findings are encouraging because they provide evidence to validate a practice that has become common among cardiologists who perform Melody valve implantation. However, they should not be construed to support universal prestenting.
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